Six-week medicine boost for depression after first treatment failure
Treatments studied
Part of Mental health clinical trials.
This study tests a more intensive antidepressant medicine approach for people whose first tried treatment didn’t work well enough. It compares the intensified treatment with usual care, aiming to improve depression symptoms and daily functioning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to 65, and you can come as an in- or out-patient
- You have major depression (not with psychosis) confirmed by a study interview
- Your first antidepressant treatment didn’t help in this episode (your clinician rates it as a failure) and you plan to switch medicines
- Your depression is at least moderate, and you have trouble with daily functioning
- If you can become pregnant: you must use effective birth control and have a negative pregnancy test at screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication added to your current treatment for chronic depression that hasn't gotten better with at least two antidepressants and 12 therapy sessions. It might help when standard treatments aren't enough.
This Phase 3 study tests a stronger medication approach after your first current treatment hasn’t worked well enough. It targets people with schizophrenia, major depressive disorder, or bipolar depression who still have significant symptoms and life impact.
This study tests whether esketamine, a nasal spray for depression, can help adults whose depression has not improved with at least two other antidepressants. Participants continue their current treatment while receiving esketamine.
This trial tests how treatment with esketamine affects metabolism in people with depression. It may help if you have not responded to at least two standard antidepressants.
This early-stage study tests ketamine and looks at what brain changes may explain why it helps people with major depression that hasn’t improved with usual treatments. You may be asked to stay in the hospital and complete detailed interviews, mood rating scales, and brain imaging.
This Phase 4 study tests whether ongoing treatment with ketamine or esketamine can reduce suicidal thoughts in people with major depression who are at high risk. Because the study focuses on long-term maintenance, you’d receive treatment over time while being closely monitored for safety and mental health changes.
Hear when a new Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.